source
- Clinical trial enrollment crisis threatens billions in revenue and patient accessClinical trials are struggling with enrollment, with about 80% missing timelines and less than 5% of eligible adult cancer patients participating. Delays have huge financial impact; each day a pha…
- North Immunology to go public via reverse merger with Aethlon, targeting eczema marketNorth Immunology, an early-stage biotech developing a dual-acting antibody for eczema, announced plans to become a public company through a reverse merger with Aethlon Medical. The transaction wil…